Frontlight ResearchEarly access
Taking peopleNo phase
Efficacy of Vonoprazan Based Dual and Triple Therapy for Patient With Helicobacter Pylori Infection
Key facts
- Who runs it
- Sohag University
- Where
- Egypt1 site in 1 countryChoose a country to see its sites
- Trial code
- Status
- Recruiting
- People taking part
- 150 people, planned
- Started
- 13 May 2025
- Planned end
- 25 Nov 2025
- Type of study
- Interventional, 3 groupsOne group gets an existing treatment, for comparison.
- Treatments tested
- Efficacy of Vonoprazan based dual therapy for naive patient with Helicobacter Pylori infection
- Efficacy of Vonoprazan based triple therapy for naive patient with Helicobacter Pylori infection
- Efficacy of PPI based triple therapy for naive patient with Helicobacter Pylori infection
- Record updated
- 1 July 2025
Who can take part
- Age
- 19 years and older
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 7 criteriaShow less
Who can take part
- Age: >18 years old
- H. pylori infection: Confirmed by histopathology or non-invasive tests (e.g., stool antigen test)
Who cannot take part
- Prior H. pylori treatment: Previous treatment for H. pylori infection
- Allergies: Known allergies to study medications or components
- Patients cannot finish treatment course
- Patient missed follow up
- Patients refusing or neglecting test of cure for H. pylori
This trial has no sites in United States.
It has sites in one country. Choose a country to see its sites.
About the trial
What the trial wants to find out
This study aims to assess Efficacy of vonoprazan based dual and triple therapy for naïve patient with Helicopacter Pylori infection in Sohag Government .
The 3 groups in the trial
- Efficacy of Vonoprazan based dual therapy for naive patient with Helicobacter Pylori infectionExisting treatment, for comparison
we assess the efficacy of Vonoprazan based dual therapy for eradication of Helicobacter Pylori infection in naive patient.
- Efficacy of Vonoprazan based triple therapy for naive patient with Helicobacter Pylori infectionExisting treatment, for comparison
we assess the efficacy of Vonoprazan based triple therapy for eradication of Helicobacter Pylori infection in naive patient.
- Efficacy of PPI based triple therapy for naive patient with Helicobacter Pylori infectionExisting treatment, for comparison
we assess the efficacy of proton pump inhibitors (PPI) based dual therapy for eradication of Helicobacter Pylori infection in naive patient.
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- Efficacy of Vonoprazan Based Dual and Triple Therapy for Naive Patient With Helicobacter Pylori Infection
- Record updated
- 1 July 2025